Our Director @ShandaBlackmon explains what factors weigh in when a surgical team decides how to take action on a secondary (metastatic) tumor in the lung. #Metastatic #LungMetastasis #LungNodule #Metastasectomy
When cancer spreads to the lungs, when should we biopsy—and when should we resect?
At the Baylor College of Medicine Lung Institute, these decisions begin with a clear goal: obtaining information that changes treatment or providing meaningful control of disease.
⚪️ Will tissue change care? Biopsy can distinguish a metastasis from a new primary lung cancer or a benign process and provide molecular information to guide therapy.
⚪️ What is the tumor’s biology? Cancer type, disease-free interval, growth rate and responsiveness to systemic therapy help determine whether local treatment makes sense.
⚪️ How many tumors are present—and where? Size, number, distribution and proximity to major airways or blood vessels affect our ability to treat lesions safely while preserving lung function.
⚪️ Can disease outside the lung be controlled? The primary tumor and other metastatic sites must fit into a coordinated treatment plan.
⚪️ Can we achieve complete treatment with acceptable risk? Lung reserve, overall health, recovery burden and the patient’s goals matter.
⚪️ Which approach best serves the goal? Options include Ion robotic navigational bronchoscopy or percutaneous biopsy, surgical resection, microwave ablation, cryoablation and stereotactic radiation. Bronchoscopic ablation and pulsed electric field therapy are emerging approaches with evolving evidence.
Careful selection is essential. Local treatment may benefit selected patients, but a survival benefit cannot be assumed for everyone. Multidisciplinary review helps match the right intervention to the right patient.
#LungMetastases #ThoracicSurgery #PrecisionOncology @bcmhouston @BCMLungInst #LungInstituteView quoted post on X
